Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascentage Pharma Group International furnishes SEC filings as a foreign private issuer reporting under Form 6-K and indicating annual reporting on Form 20-F. The filings document press releases and Hong Kong Stock Exchange announcements for annual results, oncology pipeline updates, clinical and preclinical presentation materials, and changes in corporate administration.
The company’s filing record also includes Hong Kong annual report and environmental, social and governance materials, annual general meeting notices, proxy forms, director re-election matters, general mandates to issue or repurchase shares, and supplemental equity-incentive grant proposals under its RSU and post-IPO share option schemes.
Ascentage Pharma reported extensive new clinical data for its cancer drugs olverembatinib and lisaftoclax from 17 presentations at the EHA2026 hematology congress, including eight posters. These updates span chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), chronic lymphocytic leukemia (CLL/SLL) and myeloid neoplasms.
Olverembatinib showed deep, durable responses as a second-line option for CML without T315I mutations and activity in patients resistant to multiple prior TKIs. In newly diagnosed Ph+ ALL, a registrational Phase III study reported high complete remission and MRD-negative rates with manageable safety. Combination therapy of olverembatinib and lisaftoclax in pediatric relapsed/refractory Ph+ ALL produced high response and MRD-negativity rates. Lisaftoclax also delivered promising real-world efficacy in myeloid neoplasms and meaningful activity in BTKi-refractory CLL/SLL, with analyses linking genetic risk factors to shorter progression-free survival. Both drugs are approved in China but remain investigational in the US.
Ascentage Pharma Group International reported that, on June 11, 2026, the trustee of its 2022 RSU Scheme purchased 110,000 existing shares on the market. These purchased shares, representing approximately 0.0294% of the company’s issued shares, will be used to satisfy restricted share units when they vest.
The total consideration for this purchase was about HK$3,671,094, or roughly HK$33.37 per share. After this transaction, the trustee holds 2,615,000 existing shares for the scheme. The trustee will not exercise voting rights attached to the shares it holds on trust.
Ascentage Pharma Group International reported that, on June 10, 2026, the trustee of its 2022 RSU Scheme purchased 190,000 existing shares on the market. These purchased shares, equal to approximately 0.0509% of the company’s issued share capital, will be used to satisfy restricted share units when they vest.
The total consideration for this purchase was about HK$6,418,500, at an average price of roughly HK$33.78 per share. Following this transaction, the trustee holds 2,505,000 existing shares for the 2022 RSU Scheme and will not exercise voting rights attached to these shares.
Ascentage Pharma Group International filed a Form 6-K summarizing multiple data presentations at the ASCO 2026 meeting for its oncology pipeline. The company reported its first dataset for MDM2‑p53 inhibitor alrizomadlin (APG‑115) in pediatric solid tumors, showing preliminary antitumor activity and a manageable tolerability profile. In combination with Bcl‑2 inhibitor lisaftoclax, the study reported an objective response rate of 23.5% among 17 response‑evaluable pediatric patients, including one complete response and three partial responses. Updated data for olverembatinib as second‑line therapy in chronic‑phase chronic myeloid leukemia showed a complete cytogenetic response rate of 91.3% and a major molecular response rate of 60.9% at cycle 24, with stable, manageable safety. A Phase Ib study of olverembatinib plus immunotherapy blinatumomab in CML‑LBP and Ph+ BCP‑ALL demonstrated encouraging clinical activity with minimal residual disease clearance and a safety profile consistent with the individual drugs. The company notes that alrizomadlin and olverembatinib remain under investigation and are not approved by the US FDA.
Ascentage Pharma Group International reported that the trustee of its 2022 restricted share unit (RSU) scheme bought existing shares on the market for incentive purposes. On May 28, 2026, the trustee purchased 50,000 Shares, equal to approximately 0.0134% of issued share capital.
The total consideration for these Purchased Shares was HK$1,909,800, or an average of approximately HK$38.196 per Share. Following this transaction, the trustee holds 2,315,000 existing Shares for the 2022 RSU Scheme, and will not exercise voting rights attached to shares it holds on trust.
Ascentage Pharma Group International reports that the trustee of its 2022 RSU Scheme has bought existing shares on the market to fund future share awards. On May 27, 2026, the trustee purchased 100,000 shares, about 0.0268% of issued shares, for total consideration of HK$3,977,000 at an average price of about HK$39.77 per share.
Following this transaction, the trustee holds 2,265,000 shares for the scheme. These shares are held under a trust, and the trustee will not exercise voting rights attached to them.
Ascentage Pharma Group International Chief Medical Officer Yifan Zhai reported multiple equity compensation transactions involving options, restricted stock units (RSUs), and related ordinary shares of AAPG.
On May 20, 2026, entities associated with Zhai received several awards. These included options for 298,194 ordinary shares held indirectly by a spouse at an exercise price of $6.58 per share, options for 214,988 ordinary shares directly at $6.58 per share, and options for 103,364 ordinary shares directly at $8.12 per share. Multiple RSU grants were also recorded, including 298,195, 214,999, 103,365, 95,575, and 92,746 RSUs tied to one ordinary share each upon vesting.
On May 21, 2026, RSUs vested and were converted into ordinary shares. Indirectly through a spouse, 95,575 RSUs vested into the same number of ordinary shares, resulting in 1,193,569 indirectly held ordinary shares. Directly, 92,746 RSUs vested into ordinary shares, bringing direct ordinary share holdings to 405,280 shares. No sales of shares were reported; all transactions were classified as acquisitions, grants, or exercises. Additional indirect ordinary share holdings of 22,054,131 shares held by HealthQuest Pharma Limited and 14,089,111 shares held by Dajun Yang Dynasty Trust are attributed to related entities, with beneficial ownership disclaimed except for any pecuniary interest.
ASCENTAGE PHARMA GROUP INTERNATIONAL Chairman and CEO Dajun Yang reported a series of equity compensation events, primarily vesting and grants of restricted stock units (RSUs) and options, with no open-market buying or selling.
On May 21, 2026, RSUs vested and were exercised into 92,746 ordinary shares held indirectly through his spouse and 95,575 ordinary shares held directly, increasing his reported ordinary share holdings to 405,280 indirectly and 1,193,569 directly. On May 20, 2026, Yang and his spouse received multiple new RSU and option awards at a $0.00 grant price, including a direct option grant over 298,194 ordinary shares and several indirect grants to his spouse, all scheduled to vest in installments between 2026 and 2030. Additional large indirect holdings are reported in entities such as the Dajun Yang Dynasty Trust and HealthQuest Pharma Limited, with Yang disclaiming beneficial ownership except to the extent of his pecuniary interest.
Ascentage Pharma Group International reported results of its annual general meeting and highlighted new oncology data being presented at ASCO 2026. Shareholders voted by poll on all resolutions, with each item receiving strong support based on votes cast.
They adopted audited 2025 financial statements, re-elected several directors, re-appointed Ernst & Young as auditor, and granted the board authority to issue up to 20% new shares and repurchase up to 10%. A special resolution approved a third amended and restated memorandum and articles of association. Independent shareholders also approved new RSU and option grants to CEO Dr. Yang and CMO Dr. Zhai under existing equity schemes.
The company furnished announcements and a press release noting that six clinical-study abstracts on its lead drug candidates olverembatinib, lisaftoclax, and alrizomadlin were selected for ASCO 2026, including three rapid oral and three poster presentations, several tied to ongoing phase 3 registrational trials.
Ascentage Pharma Group International furnished a Form 6-K to share a press release about upcoming scientific and investor visibility events. The company will feature 17 clinical advances at the 31st European Hematology Association Congress in Stockholm from June 11 to 14, 2026, including 8 poster presentations.
The abstracts highlight ongoing studies of Olverembatinib, China’s first approved third-generation BCR-ABL1 inhibitor, and Lisaftoclax, the first China-developed Bcl-2 selective inhibitor. The release also describes multiple global registrational Phase III trials across leukemias, lymphomas, AML, GIST and higher-risk MDS, underscoring Ascentage Pharma’s broad late-stage pipeline.